Ticker Details
Kala Pharmaceuticals, Inc. Kala Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary nanoparticle-based Mucus Penetrating Particles technology, with focus on the treatment of eye diseases.
IPO Date:	July 20, 2017
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$346.31M
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.30 | 3.81%
Avg Daily Range (30 D):	$0.02 | 4.41%
Avg Daily Range (90 D):	$0.04 | 4.96%

Institutional Daily Volume
Avg Daily Volume:	.45M
Avg Daily Volume (30 D):	.79M
Avg Daily Volume (90 D):	5.29M

Trade Size
Avg Trade Size (Sh.):	106
Avg Trade Size (Sh.) (30 D):	406
Avg Trade Size (Sh.) (90 D):	424

Institutional Trades
Total Institutional Trades:	195
Avg Institutional Trade:	$1.54M
Avg Institutional Trade (30 D):	$.59M
Avg Institutional Trade (90 D):	$.59M
Avg Institutional Trade Volume:	.02M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$2.4M
Avg Closing Trade (30 D):	$.59M
Avg Closing Trade (90 D):	$.59M
Avg Closing Volume:	7.21K

News

Dec 5, 2025 @ 7:36 PM KALA BIO Announces Closing of $10 Million Register... Source: David Lazar

Sep 29, 2025 @ 5:14 PM Crude Oil Falls Sharply; Carnival Posts Upbeat Ear... Source: Avi Kapoor

Sep 29, 2025 @ 5:06 PM 12 Health Care Stocks Moving In Monday's Intraday ... Source: Benzinga Staff Writer

Sep 29, 2025 @ 2:11 PM Nasdaq Jumps 150 Points; US Pending Home Sales Ris... Source: Avi Kapoor

Aug 8, 2025 @ 12:18 PM Kala Bio (KALA) Q2 Loss Widens 15% Source: Jesterai

Financials
	TTM	Q3 2025	Q2 2025
Basic EPS	$-5.67	$-1.07	$-1.71
Diluted EPS	$-5.66	$-1.07	$-1.71
Revenue	$M	$M	$M
Gross Profit
Net Income / Loss	$-35.84M	$-7.56M	$-11.16M
Operating Income / Loss	$-38.4M	$-7.24M	$-11.03M
Cost of Revenue
Net Cash Flow	$-28.11M	$-10.85M	$-16.56M
PE Ratio

Splits
Oct 21, 2022	1:50
Aug 26, 2022	1.00:1